FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2023-2033 November 20, 2003 Number 21 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients.

Methods The study population included 200 patients — 25 patients with nontumoral hyperprolactinemia, 105 with microprolactinomas, and 70 with macroprolactinomas. Withdrawal of cabergoline was considered if prolactin levels were normal, magnetic resonance imaging (MRI) showed no tumor (or tumor reduction of 50 percent or more, with the tumor at a distance of more than 5 mm from the optic chiasm, and no invasion of the cavernous sinuses or other critical areas), and if follow-up after withdrawal could be continued for at least 24 months.

Results Recurrence rates two to five years after the withdrawal of cabergoline were 24 percent in patients with nontumoral hyperprolactinemia, 31 percent in patients with microprolactinomas, and 36 percent in patients; with macroprolactinomas. Renewed tumor growth did not occur in any patient; in 10 female patients (22 percent) and 7 male patients (39 percent) with recurrent hyperprolactinemia, gonadal dysfunction redeveloped. In all diagnostic groups, prolactin levels at the time of recurrence were significantly lower than at diagnosis (P<0.001). The Kaplan–Meier estimated rate of recurrence at five years was higher among patients with macroprolactinomas and those with microprolactinomas who had small remnant tumors visible on MRI at the time of treatment withdrawal than among patients whose MRI scans showed no evidence of tumor at the time of withdrawal (patients with macroprolactinomas, 78 percent vs. 33 percent, P=0.001; patients with microprolactinomas, 42 percent vs. 26 percent, P=0.02).

Conclusions Cabergoline can be safely withdrawn in patients with normalized prolactin levels and no evidence of tumor. However, because the length of follow-up in our study was insufficient to rule out a delayed increase in the size of the tumor, we suggest that patients be closely monitored, particularly those with macroprolactinomas, in whom renewed growth of the tumor may compromise vision.

Source Information

From the Departments of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology (A.C., A.D.S., C.D.S., R.P., G.L.), and Neurologic Sciences, Section of Neurosurgery (P.C.) — all at Federico II University of Naples, Naples, Italy.

Address reprint requests to Dr. Colao at the Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, via S. Pansini 5, 80131 Naples, Italy, or at colao{at}unina.it.

Full Text of this Article

Related Letters:

Prolactinomas
Friedman T. C., Couldwell W. T., Weiss M. H., Laws E. R. Jr., Hortin G. L., Colao A., Lombardi G., Schlechte J.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:1054-1057, Mar 4, 2004. Correspondence

This article has been cited by other articles:

• Klibanski, A. (2009). Dopamine Agonist Therapy in Prolactinomas: When Can Treatment Be Discontinued?. J. Clin. Endocrinol. Metab. 94: 2247-2249 [Full Text]  
• Kharlip, J., Salvatori, R., Yenokyan, G., Wand, G. S. (2009). Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy. J. Clin. Endocrinol. Metab. 94: 2428-2436 [Abstract] [Full Text]  
• Martin, N. M, Tan, T., Meeran, K. (2009). Dopamine agonists and hyperprolactinaemia. BMJ 338: b381-b381 [Full Text]  
• Colao, A., Galderisi, M., Di Sarno, A., Pardo, M., Gaccione, M., D'Andrea, M., Guerra, E., Pivonello, R., Lerro, G., Lombardi, G. (2008). Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline. J. Clin. Endocrinol. Metab. 93: 3777-3784 [Abstract] [Full Text]  
• Lancellotti, P., Livadariu, E., Markov, M., Daly, A. F, Burlacu, M.-C., Betea, D., Pierard, L., Beckers, A. (2008). Cabergoline and the risk of valvular lesions in endocrine disease.. Eur J Endocrinol 159: 1-5 [Abstract] [Full Text]  
• Holt, R. I. (2008). Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 22: 28-37 [Abstract]  
• Kreutzer, J, Buslei, R, Wallaschofski, H, Hofmann, B, Nimsky, C, Fahlbusch, R, Buchfelder, M (2008). Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158: 11-18 [Abstract] [Full Text]  
• Ronchi, C. L, Rizzo, E., Lania, A. G, Pivonello, R., Grottoli, S., Colao, A., Ghigo, E., Spada, A., Arosio, M., Beck-Peccoz, P. (2008). Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158: 19-25 [Abstract] [Full Text]  
• Kars, M, van der Klaauw, A A, Onstein, C S, Pereira, A M, Romijn, J A (2007). Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol 157: 133-139 [Abstract] [Full Text]  
• Schlechte, J. A. (2007). Long-Term Management of Prolactinomas. J. Clin. Endocrinol. Metab. 92: 2861-2865 [Abstract] [Full Text]  
• Fedele, M., De Martino, I., Pivonello, R., Ciarmiello, A., Del Basso De Caro, M. L., Visone, R., Palmieri, D., Pierantoni, G. M., Arra, C., Schmid, H. A., Hofland, L., Lombardi, G., Colao, A., Fusco, A. (2007). SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clin. Cancer Res. 13: 2738-2744 [Abstract] [Full Text]  
• Ferone, D., Pivonello, R., Resmini, E., Boschetti, M., Rebora, A., Albertelli, M., Albanese, V., Colao, A., Culler, M. D, Minuto, F. (2007). Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156: S37-S43 [Abstract] [Full Text]  
• de Herder, W. W, Reijs, A. E M, Feelders, R. A, van Aken, M. O, Krenning, E. P, Tanghe, H. L J, van der Lely, A.-J., Kwekkeboom, D. J (2006). Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?. Eur J Endocrinol 155: 717-723 [Abstract] [Full Text]  
• Gillam, M. P., Molitch, M. E., Lombardi, G., Colao, A. (2006). Advances in the Treatment of Prolactinomas. Endocr. Rev. 27: 485-534 [Abstract] [Full Text]  
• Delgrange, E., Pinero, A., Marcos-Alberca, P., Fortes, J. (2006). Cabergoline and Mitral Regurgitation. NEJM 354: 420-420 [Full Text]  
• Fernando, M. A., Heaney, A. P. (2005). {alpha}1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary Adenomas. Mol. Endocrinol. 19: 3085-3096 [Abstract] [Full Text]  
• Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., Lombardi, G. (2004). Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. J. Clin. Endocrinol. Metab. 89: 1704-1711 [Abstract] [Full Text]  
• Friedman, T. C., Couldwell, W. T., Weiss, M. H., Laws, E. R. Jr., Hortin, G. L., Colao, A., Lombardi, G., Schlechte, J. (2004). Prolactinomas. NEJM 350: 1054-1057 [Full Text]